Carisma Therapeutics Inc.: stockholders equity
Stockholders equity for Carisma Therapeutics Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Carisma Therapeutics Inc. financial histories
What this measure means
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2011-12-31 to 2023-12-31. The SEC response was captured on 2026-09-21.
This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2023-12-31 | 26,532,000 | USD | 2024-04-01 | 10-K · 0001485003-24-000005 |
| At date | 2022-12-31 | -157,065,000 | USD | 2024-04-01 | 10-K · 0001485003-24-000005 |
| At date | 2021-12-31 | 171,710,000 | USD | 2023-02-28 | 10-K · 0001485003-23-000090 |
| At date | 2020-12-31 | -9,227,000 | USD | 2023-02-28 | 10-K · 0001485003-23-000090 |
| At date | 2019-12-31 | -26,700,000 | USD | 2023-02-28 | 10-K · 0001485003-23-000090 |
| At date | 2018-12-31 | 44,207,000 | USD | 2022-02-28 | 10-K · 0001485003-22-000033 |
| At date | 2017-12-31 | 18,034,000 | USD | 2021-03-15 | 10-K · 0001485003-21-000044 |
| At date | 2016-12-31 | 38,677,000 | USD | 2020-03-16 | 10-K · 0001485003-20-000038 |
| At date | 2015-12-31 | 18,944,000 | USD | 2019-03-01 | 10-K · 0001485003-19-000015 |
| At date | 2014-12-31 | 36,826,000 | USD | 2018-04-02 | 10-K · 0001485003-18-000034 |
| At date | 2013-12-31 | -54,332,000 | USD | 2017-03-24 | 10-K · 0001485003-17-000018 |
| At date | 2012-12-31 | -39,296,000 | USD | 2016-03-25 | 10-K · 0001485003-16-000068 |
| At date | 2011-12-31 | -19,791,000 | USD | 2015-03-06 | 10-K · 0001193125-15-081274 |
Related financial histories
- Carisma Therapeutics Inc.: total assets
- Carisma Therapeutics Inc.: total liabilities
- Carisma Therapeutics Inc.: cash and cash equivalents
- Carisma Therapeutics Inc.: net income or loss
- Carisma Therapeutics Inc.: operating cash flow
- Carisma Therapeutics Inc.: capital expenditure payments
- Carisma Therapeutics Inc.: revenue
- Carisma Therapeutics Inc.: contract revenue excluding tax
- Carisma Therapeutics Inc.: financing cash flow
- Carisma Therapeutics Inc.: investing cash flow
- Carisma Therapeutics Inc.: retained earnings or deficit
- Carisma Therapeutics Inc.: basic weighted-average shares
- Carisma Therapeutics Inc.: diluted weighted-average shares
- Carisma Therapeutics Inc.: basic earnings per share
- Carisma Therapeutics Inc.: diluted earnings per share
- Carisma Therapeutics Inc.: income tax expense or benefit
- Carisma Therapeutics Inc.: net property, plant and equipment
- Carisma Therapeutics Inc.: share-based compensation expense
- Carisma Therapeutics Inc.: operating income or loss
- Carisma Therapeutics Inc.: current assets
- Carisma Therapeutics Inc.: current liabilities
- Carisma Therapeutics Inc.: current accounts payable
- Carisma Therapeutics Inc.: goodwill carrying amount
- Carisma Therapeutics Inc.: net current accounts receivable
- Carisma Therapeutics Inc.: operating expenses
- Carisma Therapeutics Inc.: research and development expense
- Carisma Therapeutics Inc.: common shares outstanding
- Carisma Therapeutics Inc.: cash including restricted cash
- Carisma Therapeutics Inc.: additional paid-in capital
- Carisma Therapeutics Inc.: accumulated other comprehensive income or loss
- Carisma Therapeutics Inc.: total equity including noncontrolling interests
- Carisma Therapeutics Inc.: operating lease right-of-use asset
- Carisma Therapeutics Inc.: operating lease liability
- Carisma Therapeutics Inc.: gross property, plant and equipment
- Carisma Therapeutics Inc.: accumulated depreciation on property, plant and equipment
- Carisma Therapeutics Inc.: net intangible assets excluding goodwill
- Carisma Therapeutics Inc.: other noncurrent assets
- Carisma Therapeutics Inc.: other noncurrent liabilities
- Carisma Therapeutics Inc.: accrued current liabilities
- Carisma Therapeutics Inc.: prepaid expenses and other current assets
- Carisma Therapeutics Inc.: current contract liabilities
- Carisma Therapeutics Inc.: net deferred tax assets
- Carisma Therapeutics Inc.: net deferred tax liabilities
- Carisma Therapeutics Inc.: pre-tax income or loss from continuing operations
- Carisma Therapeutics Inc.: comprehensive income or loss
- Carisma Therapeutics Inc.: net income available to common stockholders
- Carisma Therapeutics Inc.: general and administrative expense
- Carisma Therapeutics Inc.: other nonoperating income or expense
- Carisma Therapeutics Inc.: nonoperating income or expense
- Carisma Therapeutics Inc.: current income tax expense or benefit
- Carisma Therapeutics Inc.: deferred income tax expense or benefit
- Carisma Therapeutics Inc.: interest paid, net
- Carisma Therapeutics Inc.: proceeds from issuing common stock
- Carisma Therapeutics Inc.: operating lease payments
- Carisma Therapeutics Inc.: change in accounts receivable
- Carisma Therapeutics Inc.: change in accounts payable
Inspect the source
- Entity
- Carisma Therapeutics Inc. / CIK 0001485003
- Captured
- 2026-09-21T17:19:20.826Z
- SEC response SHA-256
d62cca0d8221b3738cba25e71f5eb35e1ed429922b023abc1976ffd54285c087
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001485003.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))